MARKETS / NOTVQ
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · MID CAP
Inotiv, Inc. NOTVQ
16 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 513.0M
Revenue, FY2025 · full 16-year series below
Revenue $M
Net income $M
FY2025 · Revenue 513.0 · Net income -68.6
Compound annual growth
Revenue compounded at +53.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−13 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -6.0% · Net -13.4%
ROE
FY2025 · ROE -44.8%
Each USD of equity lost 45 cents this year.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.5 | 0.5 | 0.6 | 0.5 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.1 | −0.1 | −0.3 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 |
| EBITDA $B | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | · |
| Income tax $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.3 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | · | · |
| EPS, diluted $ | −2.11 | −4.19 | −4.10 | −13.84 | 0.19 | −0.43 | −0.08 | −0.02 | 0.10 | −0.40 | 0.07 | −0.13 | 0.09 | −0.88 | −0.74 | −0.55 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −44.8 | −49.3 | −33.4 | −144.8 | 19.3 | −51.2 | −7.3 | −2.0 | 11.1 | −35.5 | 10.8 | −11.3 | 8.7 | −55.7 | 18.4 | −25.2 |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 76 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 19 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onnot stated in the filings
Incorporated inIndiana
Fiscal year endsSeptember 30
Data on record since2010